Expression Of ARID1A And CHK2 Protein In Ovarian Endometrioid Carcinoma Cells

Background:Ovarian Malignant Tumor, which is also known as ovarian cancer, is one of the most frequent cause of deaths from among gynecologic malignancies. Due to its asymptomatic development, the disease is frequently diagnosed at an advanced, incurable stages. Despite many years of studies of its histologic and molecular features, there is still lack of reliable diagnostic markers as well as other diagnostic methods enabling early detection and suitable for screening. Thus, current studies are aimed on finding new biomarkers with diagnostic, prognostic and predictive potential as well as on the search for the new therapeutic targets.Objective:1. To obtain the percentage of aberrant protein expression of Gene ARID1A and Gene CHK2 in ovarian endometrioid carcinoma by immunohistochemistry analysis.2. To acquire the relationship between Gene ARID1A mutation and endometriosis-associated ovarian carcinoma, by analyzing the expression of Gene ARID1A in endometriosis and ovarian endometrioid carcinoma.3. To bring light on identifications of the key functional gene in malignant transformation of endometriosis.4. To acquire the relationship between abnormal Gene CHK2 expression and the clinical staging of ovarian endometrioid carcinoma.Methods:This study was conducted on all patients who were satisfied with following conditions:The patients who were diagnosed with ovarian endometrioid carcinoma and underwent surgery between January 2015 and January 2016 in department of Gynecological and Obstetrics in Peking Union Medical College Hospital, Beijing, China. And the patients, who were once diagnosed with endometriosis and then ovarian endometrioid carcinoma, and had both tumor excision during January 1995 and March 2016, were also included. We get the information of aberrant expression of Gene ARID1A and CHK2 in ovarian endometrioid carcinoma by immunohistochemistry, in order to find out either of the two genes could be new biomarkers with diagnostic, prognostic and predictive potential of the disease.Results:1. The aberrant protein expression rate of Gene ARID1A is 44%, and CHK2 is 36% in ovarian endometrioid carcinoma.2. The abnormal expression rate of Gene ARID1A in ovarian endometrioid carcinoma patients with endometriosis is 66.7%.3. More times of chemotherapy were always. needed by the patients with dysregulated expression of Gene ARID 1 A, before their level of CA125 got normal.4. There is no statistic difference between age, clinical staging, level of CA125, pathological grading, lymphatic metastasis and platinum-resistant in patients with or without aberrant protein expression of Gene CHK2.Conclusion:1. The aberrant expression rate of Gene ARID1A and Gene CHK2 in 25 ovarian endometrioid carcinoma patients indicates that both of the genes have close relationships with the formation of ovarian endometrioid carcinoma.2. The abnormal protein expression rate of Gene ARID1A in patients with endometriosis is 66.7%, along with a high percentage of abnormal Gene ARID1A expression in endometriosis, reminds us that the gene may play an important role in endometriosis malignant.3. The dysregulated expression of CHK2 performs no statistic difference in clinical data of ovarian endometrioid carcinoma patients, which indicates that CHK2 is not an effective biomarker with prognostic and predictive potential of the disease.